Lawrence A. Leiter
St. Michael's Hospital
EndocrinologyCardiologyType 2 diabetesDiabetes mellitusMedicine
What is this?
Publications 514
#1Manige Konig (Eli Lilly and Company)H-Index: 1
#1Manige Konig (Eli Lilly and Company)H-Index: 1
view all 10 authors...
#1Lawrence A. Leiter (St. Michael's Hospital)H-Index: 71
#2Stephen C. Bain (Swansea University)H-Index: 25
Last. Subodh Verma (St. Michael's Hospital)H-Index: 70
view all 10 authors...
It is unknown if the cardioprotective and renal effects of glucagon-like peptide-1 receptor agonists are consistent across blood pressure (BP) categories in patients with type 2 diabetes and at high risk of cardiovascular events. Using data from the LEADER (9340 patients) and SUSTAIN 6 (3297 patients) trials, we evaluated post hoc the cardiorenal effect of liraglutide and semaglutide on major adverse cardiovascular events (MACE) and nephropathy by baseline BP categories using a Cox proportional ...
#1Doreen M. Rabi (U of C: University of Calgary)H-Index: 24
#2Kerry McBrien (U of C: University of Calgary)H-Index: 13
Last. Lyne Cloutier (Université du Québec à Trois-Rivières)H-Index: 13
view all 82 authors...
Abstract Hypertension Canada's 2020 guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children provide comprehensive, evidence-based guidance for health care professionals and patients. Hypertension Canada develops the guidelines using rigourous methodology, carefully mitigating the risk of bias in our process. All draft recommendations undergo critical review by expert methodologists without conflict to ensure quality. Our guideline panel is ...
2 CitationsSource
#1Lawrence A. LeiterH-Index: 71
#2Stephen C. BainH-Index: 25
view all 10 authors...
#1Lawrence A. Leiter (St. Michael's Hospital)H-Index: 71
This review addresses the question of the cardiovascular (CV) safety of sulfonylureas (SUs) in patients with type 2 diabetes mellitus (T2DM) when directly tested against comparator agents in CV outcome trials. Presented at a recent symposium entitled "SUs in the treatment of T2DM: a fresh look and new insights" held on Wednesday September 18, 2019 during the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona Spain, this review discusses the initial evid...
#1Suzanne V. Arnold (UMKC: University of Missouri–Kansas City)H-Index: 15
#2Kensey Gosch (UMKC: University of Missouri–Kansas City)H-Index: 18
Last. Mikhail Kosiborod (UMKC: University of Missouri–Kansas City)H-Index: 46
view all 7 authors...
#1Suzanne V. ArnoldH-Index: 29
#2Deepak L. BhattH-Index: 122
Last. Jonathan D. NewmanH-Index: 16
view all 11 authors...
Although cardiologists have long treated patients with coronary artery disease (CAD) and concomitant type 2 diabetes mellitus (T2DM), T2DM has traditionally been considered just a comorbidity that affected the development and progression of the disease. Over the past decade, a number of factors have shifted that have forced the cardiology community to reconsider the role of T2DM in CAD. First, in addition to being associated with increased cardiovascular risk, T2DM has the potential to affect a ...
#1David Fitchett (St. Michael's Hospital)H-Index: 41
#1David H. FitchettH-Index: 17
Last. Anil GuptaH-Index: 6
view all 11 authors...
Abstract A recent acute coronary syndrome (ACS) provides an opportunity to optimise secondary prevention strategies to reduce the risk of future cardiovascular events. This review provides an updated synopsis of current evidence-based approaches. New clinical trial data on the use of antiplatelet and anticoagulants allows choices of the selection and duration of treatment. Lipid lowering after an ACS is now enhanced, with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors providing...
#1Ulf Landmesser (Charité)H-Index: 74
#2Arash Haghikia (Charité)H-Index: 18
Last. Kausik K. Ray (Imperial College London)H-Index: 54
view all 9 authors...
INTRODUCTION: siRNA-based targeting of PCSK9 represents a novel therapeutic approach that may provide a convenient, infrequent and safe dosing schedule to robustly lower LDL-C. Given the long duration of action, however, establishing safety in particular with respect to immunogenicity is of paramount importance. In earlier clinical studies of other RNA-targeted treatment approaches (antisense oligonucleotide therapy) immunological and haematological adverse-effects, in particular thrombocytopeni...
#1Avivit Cahn (HUJI: Hebrew University of Jerusalem)H-Index: 17
#2Itamar Raz (HUJI: Hebrew University of Jerusalem)H-Index: 49
Last. Darren K. McGuire (UTSW: University of Texas Southwestern Medical Center)H-Index: 67
view all 19 authors...
AIMS: To comprehensively evaluate the safety of dapagliflozin in patients with type 2 diabetes (T2DM) with emphasis placed on potential safety concerns related to the SGLT2-inhibitors class. METHODS: In DECLARE-TIMI 58, 17,160 patients with T2DM were randomized to dapagliflozin or placebo and followed for a median of 4.2 years. Safety was evaluated in 17,143 patients receiving at least one dose of study drug. RESULTS: Acute kidney injury occurred less frequently with dapagliflozin, and adverse e...